Genmab A (GMAB) Net Income towards Common Stockholders: 2018-2021
- Genmab A's Net Income towards Common Stockholders rose 362.62% to $169.09 in Q2 2021 from the same period last year, while for Jun 2021 it was $356.29, marking a year-over-year decrease of 100.00%. This contributed to the annual value of $552.7 million for FY2020, which is 145.38% up from last year.
- According to the latest figures from Q2 2021, Genmab A's Net Income towards Common Stockholders is $169.09, which was up 116.92% from $77.95 recorded in Q4 2020.
- Over the past 5 years, Genmab A's Net Income towards Common Stockholders peaked at $25.5 million during Q4 2018, and registered a low of -$11.7 million during Q2 2019.
- Its 3-year average for Net Income towards Common Stockholders is -$2.3 million, with a median of $72.69 in 2019.
- Per our database at Business Quant, Genmab A's Net Income towards Common Stockholders slumped by 100.00% in 2019 and then surged by 362.62% in 2021.
- Over the past 4 years, Genmab A's Net Income towards Common Stockholders (Quarterly) stood at $25.5 million in 2018, then crashed by 100.00% to $72.69 in 2019, then climbed by 7.23% to $77.95 in 2020, then soared by 362.62% to $169.09 in 2021.
- Its Net Income towards Common Stockholders stands at $169.09 for Q2 2021, versus $77.95 for Q4 2020 and $36.55 for Q2 2020.
